INSERM, UMR1260 University of Strasbourg - France
Author Profile
ORCID
Early academic pursuits 🎓
Canan G. Nebigil-Désaubry embarked on her academic journey with a pharm.d. from ankara university, where her interest in pharmacology and molecular biology began to take shape. she further pursued a ph.d. at the university of tennessee, delving deeper into molecular signaling pathways. her academic excellence and passion for biomedical research led her to postdoctoral training under nobel laureate professor robert lefkowitz at duke university, where she gained invaluable insights into g protein-coupled receptors (gpcrs), setting the stage for her future research.
Professional endeavors 💼
After completing her postdoctoral training, dr. nebigil-désaubry's career flourished as a senior scientist at the national institutes of health (nih) and later at the institute of genetics and molecular and cellular biology (igbmc). her exemplary work earned her an atip/avenir award, enabling her to join the european school of biotechnology (esbs) at the university of strasbourg. currently, she serves as the director of research at cnrs, inserm umr1260 regenerative nanomedicine, where she continues to make significant contributions to cardiovascular and metabolic research.
Contributions and research focus 🔬
Dr. Nebigil-désaubry's research primarily explores the role of gpcrs, particularly serotonin and prokineticin receptors, in cardiovascular development and disease. she established the critical Cardiovascular roles of these receptors in heart development and pathology, notably identifying the serotonin 5-ht2b receptor's pivotal role in embryonic cardiac development. her team was also the first to investigate prokineticin signaling in cardiac and metabolic disorders, revealing its potential as a therapeutic target for heart disease, obesity, and diabetes. her groundbreaking discovery of the first non-peptidic pkr1 agonist, is20, marked a significant milestone in cardioprotection and cardio-oncology.
Accolades and recognition 🏆
Dr. Nebigil-désaubry's innovative research has earned her numerous accolades, including the prestigious atip/avenir award. her contributions to cardiovascular and metabolic research are Cardiovascular recognized globally, with multiple drug discovery patents to her name. the inclusion of is20 in the international union of basic and clinical pharmacology (iuphar) guide to pharmacology as a selective pkr1 agonist further underscores the significance of her work in the scientific community.
Impact and influence 💡
The impact of dr. nebigil-désaubry's research extends beyond academic circles, influencing clinical practices and therapeutic strategies in cardiology and oncology. her identification of the Cardiovascular prokineticin/pkr1 signaling pathway as a regulator of epicardial adipose tissue development has provided new avenues for managing heart failure with preserved ejection fraction (hfpef) and cardiometabolic disorders. her work in cardio-oncology aims to address the pressing need for early biomarkers and cardioprotective therapeutics in chemotherapy-induced heart failure.
Legacy and future contributions 🕊️
Dr. Nebigil-désaubry's legacy is one of innovation and excellence in cardiovascular research. her pioneering work in cardiac regeneration and metabolic disease management has laid the foundation for future advancements in precision medicine. with her recent development of a 3d cardiac organoid-tumor system, she is poised to accelerate drug discovery and biomarker identification, ultimately improving patient outcomes and shaping the future of regenerative medicine and cardio-oncology.
Notable Publications
-
Title: Flavaglines: Their Discovery from Plants Used in Traditional Chinese Medicine, Synthesis, and Drug Development Against Cancer and Immune Disorders
Author(s): Dong Wang, Mustafa Ali Tezeren, Hussein Abou Hamdan, Peng Yu, Canan Nebigil-Désaubry, Laurent Désaubry
Journal: Current Chinese Chemistry, 2022
-
Title: Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases
Author(s): Dong Wang, Redouane Tabti, Sabria Elderwish, Hussein Abou-Hamdan, Amel Djehal, Peng Yu, Hajime Yurugi, Krishnaraj Rajalingam, Canan G. Nebigil, Laurent Désaubry
Journal: Cellular and Molecular Life Sciences, 2020
-
Title: SFPH proteins as therapeutic targets for a myriad of diseases
Author(s): Dong Wang, Redouane Tabti, Sabria Elderwish, Amel Djehal, Nora Chouha, Franck Pinot, Peng Yu, Canan G. Nebigil, Laurent Desaubry
Journal: Bioorganic and Medicinal Chemistry Letters, 2020
-
Title: Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses
Author(s): Canan G. Nebigil, Christiane Moog, Stéphan Vagner, Nadia Benkirane-Jessel, Duncan Smith, Laurent Désaubry
Journal: European Journal of Medicinal Chemistry, 2020
-
Title: Prokineticin signaling in heart-brain developmental axis: Therapeutic options for heart and brain injuries
Author(s): Laurent Désaubry, Anumantha Kanthasamy, Canan G. Nebigil
Journal: Pharmacological Research, 2020